Clinical Study on the Safety and Efficacy of Anti-Mesothelin Car NK Cells With Epithelial Ovarian Cancer

NCT03692637 EARLY_PHASE1 UNKNOWN

This is a single centre、single arm、open-label，to investigate the safety and efficacy of anti-Mesothelin Car NK Cells With Epithelial ovarian cancer

Details

Lead sponsor	Allife Medical Science and Technology Co., Ltd.
Phase	EARLY_PHASE1
Status	UNKNOWN
Enrolment	30
Start date	2019-03
Completion	2021-11

Conditions

• Epithelial Ovarian Cancer

Interventions

• anti-Mesothelin Car NK Cells

Primary outcomes

• Occurrence of treatment related adverse events as assessed by CTCAE v4.0 — Day 3-Year 2 after injection
  defined as \>= Grade 3 signs/symptoms, laboratory toxicities, and clinical events that are possibly, likely, or definitely related to study treatment